Showing 4711-4720 of 7346 results for "".
- Practical Dermatology Joins the ReachMD Network to Expand Audiences, Channels, and Content Syndicationhttps://practicaldermatology.com/news/practical-dermatology-joins-reachmd-network-expand-audiences-channels-and-content-syndication/2467450/Practical Dermatology today announced its partnership with ReachMD to syndicate its vast content library across all channels of the ReachMD Network, which includes websites, mobile apps, email newsletters, social channels, live events, radio stations, social me
- TRuE-AD3: Ruxolitinib Cream Safe in Pediatric Atopic Dermatitis Patientshttps://practicaldermatology.com/news/true-ad3-ruxolitinib-cream-safe-pediatric-atopic-dermatitis-patients/2467445/Ruxolitinib applied twice daily did not appear to impact hematologic parameters in any clinically meaningful way, according to a new study. "In two randomized phase 3 studies (TRuE-AD1 and TRuE-AD2) evaluating ruxolitinib (Janus kinase [JAK]1/JAK2 inhibitor) cream in adults and adolescent
- Study: CBD Cream Shows Promise in Reducing Sun-Induced Skin Injuryhttps://practicaldermatology.com/news/study-cbd-cream-shows-promise-reducing-sun-induced-skin-injury/2467423/New research from the George Washington University School of Medicine and Health Sciences, in collaboration with the Center for Clinical and Cosmetic Research, suggests that cannabidiol (CBD) has potential in preventing skin damage from ultraviolet-A (UVA) radiation. Researchers for the 1
- Dermaliq Therapeutics Announces Positive Topline Results from Phase 1b/2a Trial of Androgenetic Alopecia Treatmenthttps://practicaldermatology.com/news/dermaliq-therapeutics-announces-positive-topline-results-phase-1b2a-trial-androgenetic-alopecia-treatment/2467422/Dermaliq Therapeutics announced statistically significant topline data from a randomized, blinded, vehicle and comparator-controlled clinical phase 1b/2a trial in men with androgenetic alopecia (male pattern baldness, AGA) for its topical product candidate DLQ01, a prostaglandin F2α analog, based
- Taylor Fritz Partners with La Roche-Posay for Sun Safety Campaignhttps://practicaldermatology.com/news/taylor-fritz-partners-la-roche-posay-sun-safety-campaign/2467419/La Roche-Posay has partnered with professional tennis player Taylor Fritz to promote awareness of sun safety practices, according to a news release. Taylor Fritz, currently the highest-ranked American male tennis player, will serve as the sun safety spokesperson for La Roche-Posay to high
- Study: Dupilumab Shows Sustained Benefit for Severe ADhttps://practicaldermatology.com/news/study-dupilumab-shows-sustained-benefit-severe-ad/2467337/New research on the long-term safety and efficacy of dupilumab in adults with moderate to severe atopic dermatitis (AD) indicates that dupilumab was safe and effective in the long-term treatment of the condition. The open-label extension study was conducted over a period of 5 years in 28
- Study: Omega-3 Supplementation Reduces Acne Severityhttps://practicaldermatology.com/news/study-omega-3-supplementation-reduces-acne-severity/2467299/New research suggests there may be potential benefits of omega-3 fatty acids (ω-3 FA) in managing acne severity through dietary intervention and supplementation. Study researchers publishing in the Journal of Cosmetic Dermatology focused their efforts on eicosapentaenoic acid (EP
- Platelet-Rich Plasma Improves Outcomes in Severe ADhttps://practicaldermatology.com/news/platelet-rich-plasma-improves-outcomes-severe-ad/2467268/A new study looking at platelet-rich plasma (PRP) as an adjuvant therapy for adult atopic dermatitis (AD) suggested the treatment was associated with favorable outcomes. The literature search focused on original English-language articles about PRP as a therapeutic method for adult AD. Revi
- Promotional vs. Educational: Skin Condition Posts on Instagram and TikTokhttps://practicaldermatology.com/news/promotional-vs-educational-skin-condition-posts-instagram-and-tiktok/2467249/New research revealed differences in the types of dermatology content present on the Instagram and TikTok social media platforms. Researchers publishing in the Journal of Drugs in Dermatology looked specifically at content on the Instagram and TikTok social media platforms relat
- Survey: Just 40% See Dermatologists Annually Despite Skin Concernshttps://practicaldermatology.com/news/survey-just-40-see-dermatologists-annually-despite-skin-concerns/2467226/Manufacturer CeraVe has announced findings from a new survey suggesting that while 80% of participants experienced skin concerns, just 40% of them visited a dermatologist for an annual skin exam. The survey of 1,000 American adults also revealed that 25% suffered from serious skin condit